Publications by authors named "I D Arnott"
Background And Aims: Over the last decade, treatment options for moderate-to-severe ulcerative colitis (UC) have expanded. However, comparative studies between these agents are limited, especially among biologic-naïve patients. We aimed to compare the persistence, effectiveness and safety of tofacitinib and vedolizumab as the first advanced treatment for patients with UC.
View Article and Find Full Text PDFBackground: Long-term vedolizumab (VDZ) outcomes in real-world cohorts have been largely limited to 1-year follow-up, with few bio-naïve patients or objective markers of inflammation assessed.
Objectives: We aimed to assess factors affecting VDZ persistence including clinical, biochemical and faecal biomarker remission at 1, 3 and 5 years.
Design: We performed a retrospective, observational, cohort study.
Article Synopsis
- The study aimed to evaluate the effectiveness of early medical prophylaxis versus waiting for endoscopy findings in preventing postoperative recurrence (POR) in patients with Crohn's disease after ileocaecal resection (ICR).
- Out of 346 patients, those receiving early prophylactic treatment (Cohort 1) had significantly lower endoscopic recurrence rates compared to those who only received treatment based on endoscopy results (Cohort 2).
- While both groups did not show significant differences in severe endoscopic POR or time to surgical recurrence, the proactive group had a lower treatment burden when using immunomodulators.
Background: Filgotinib is a small molecule with preferential inhibition of Janus kinase type 1, approved for the treatment of ulcerative colitis in Scotland in May 2022. We present the first real world experience on its use in clinical practice.
Methods: In this retrospective, observational, cohort study we assessed patients with active ulcerative colitis who received filgotinib in NHS Lothian, Scotland.
Article Synopsis
- The ACE Index was initially developed to predict steroid non-response in patients with acute ulcerative colitis (UC) and has now been validated in a larger, independent patient cohort.
- In a study of 800 patients, the ACE Index showed a positive predictive value of 62.5% for those scoring a maximum of 3, indicating a significant portion did not respond to IV steroids, while 79.8% of patients with a score of 0 did respond.
- The validation suggests the ACE Index can assist in identifying high-risk patients for steroid non-response in acute UC cases, but further research is needed to enhance its accuracy and clinical application.